HRTX · Heron Therapeutics, Inc. /De/

$0.34 +0.01 (+4.21%) At close · Sep 4

Russell 2000 member Rebalance outlook locked

Market Cap

$65.29M

189.85M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Hensley	EVP, Chief Operating Officer	$372,212	—	$1,210,000	$2,527,680	$187,108	$10,500	$4,307,500
Craig Collard	Chief Executive Officer	$689,431	—	$946,254	$1,352,917	$517,189	$10,500	$3,516,291
William Forbes	EVP, Chief Development Officer	$609,881	—	$318,087	$454,788	$305,009	—	$1,687,765
Ira Duarte	EVP, Chief Financial Officer	$559,803	—	$318,087	$454,788	$287,500	$10,500	$1,630,678

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ira Duarte	EVP, Chief Financial Officer	$592,250	—	$129,557	$473,779	$340,544	—	$1,536,130
William Forbes	EVP, Chief Development Officer	$592,250	—	$129,557	$473,779	$340,544	—	$1,536,130
Craig Collard	Chief Executive Officer	$515,000	—	$129,557	$473,779	$296,125	$10,350	$1,424,811
Mark Hensley	EVP, Chief Operating Officer	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Collard	Chief Executive Officer	$492,986	—	$547,273	$9,257,049	$326,957	$151,553	$10,775,818
Ira Duarte	EVP, Chief Financial Officer	$271,154	—	$60,500	$1,066,875	$128,844	$7,500	$1,534,873
William Forbes	EVP, Chief Development Officer	$329,519	—	$55,500	$917,433	$155,654	—	$1,458,106
Mark Hensley	EVP, Chief Operating Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kimberly Manhard	Executive Vice President, Drug Development	$545,834	—	$441,456	$235,482	$204,688	$19,647	$1,447,107
David Szekeres	Executive Vice President, Chief Commercial Officer	$533,013	—	$441,456	$235,482	$199,880	$19,400	$1,429,231
Barry Quart	Pharm.D. Former Chief Executive Officer	$736,000	—	—	—	$386,400	$23,304	$1,145,704
Craig Collard	Chief Executive Officer	—	—	—	—	—	—	—
Ira Duarte	EVP, Chief Financial Officer	—	—	—	—	—	—	—
William Forbes	EVP, Chief Development Officer	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	Pharm.D. Former Chief Executive Officer	$700,000	—	$2,061,649	$2,268,479	$392,000	$8,700	$5,430,828
Kimberly Manhard	Executive Vice President, Drug Development	$514,937	—	$583,626	$535,147	$205,975	$18,893	$1,858,578
John Poyhonen	President and Chief Commercial Officer	$509,748	—	$583,626	$535,147	$203,899	$8,700	$1,841,120
David Szekeres	Executive Vice President, Chief Commercial Officer	$494,400	—	$583,626	$535,147	$197,760	$18,498	$1,829,431
Lisa Peraza	Vice President, Chief Accounting Officer	$339,900	—	$247,123	$75,530	$118,965	$15,237	$796,755

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	Pharm.D. Chief Executive Officer	$676,838	—	$916,995	$3,366,895	$364,991	$21,084	$5,346,803
John Poyhonen	President and Chief Commercial Officer	$513,935	—	$314,400	$1,635,349	$197,960	$8,550	$2,670,194
David Szekeres	Executive Vice President, Chief Operating Officer	$476,910	—	$314,400	$1,500,673	$161,664	$8,550	$2,462,197
Kimberly Manhard	Executive Vice President,	$519,167	—	$314,400	$1,154,364	$199,976	$8,550	$2,196,457
Lisa Peraza	Vice President, Chief Accounting Officer	$328,805	—	$138,855	$990,829	$105,683	$14,567	$1,578,739
Robert Hoffman	Former Chief Financial Officer and Senior Vice President, Finance	$360,009	—	—	—	—	$668,287	$1,028,296

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	Pharm.D. Chief Executive Officer	$638,991	—	—	$4,916,373	$306,715	$8,400	$5,870,479
John Poyhonen	President and Chief Commercial Officer	$216,731	—	—	$4,211,063	$90,751	$6,219	$4,524,764
Drug Development	—	$490,136	—	—	$1,815,276	$196,054	$8,400	$2,509,866
Kimberly Manhard	Executive Vice President,	$490,136	—	—	$1,815,276	$196,054	$8,400	$2,509,866
Robert Hoffman	Former Chief Financial Officer and Senior Vice President, Finance	$388,714	—	—	$1,512,730	$124,388	$8,400	$2,034,232
Robert Rosen	Former President	$78,645	—	—	—	—	$1,022,386	$1,101,031

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	Pharm.D. Chief Executive Officer	$614,414	—	—	$4,815,660	$552,973	$8,250	$5,991,297
Robert Rosen	Former President	$614,414	—	—	$4,815,660	$552,973	—	$5,983,047
Kimberly Manhard	Executive Vice President,	$466,796	—	—	$1,605,220	$350,097	$8,250	$2,430,363
Drug Development	—	$466,796	—	—	$1,605,220	$350,097	$8,250	$2,430,363
Robert Hoffman	Former Chief Financial Officer and Senior Vice President, Finance	$357,438	—	—	$1,139,706	$214,463	$8,027	$1,719,634
John Poyhonen	Executive Vice President, Chief Commercial Officer	—	—	—	—	—	—	—

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	Pharm.D. President and Chief Executive Officer	$596,518	—	—	$3,391,524	$246,958	$8,100	$4,243,100
Robert Rosen	Former President	$596,518	—	—	$3,391,524	$246,958	—	$4,235,000
Robert Hoffman	Chief Financial Officer and Senior Vice President, Finance	$235,577	—	—	$1,972,207	$68,425	$3,635	$2,279,844
Drug Development	—	$453,200	—	—	$1,312,848	$156,354	$8,100	$1,930,502
John Poyhonen	Executive Vice President, Chief Commercial Officer	—	—	—	—	—	—	—

Key facts CIK 818033 CUSIP 427746102 13F (30d) 108 filings 108 filers Visit website Investor relations